Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
Adult
Aged
Antineoplastic Agents, Immunological
/ administration & dosage
Drug Resistance, Neoplasm
Female
Humans
Immunoconjugates
/ administration & dosage
Male
Maytansine
/ administration & dosage
Middle Aged
Multiple Myeloma
/ diagnosis
Neoplasm Grading
Neoplasm Staging
Recurrence
Treatment Outcome
Antibody-drug conjugate
CD138
Monoclonal antibody
Multiple-dose
Syndecan-1
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
02
11
2018
accepted:
11
02
2019
pubmed:
2
4
2019
medline:
28
7
2020
entrez:
2
4
2019
Statut:
ppublish
Résumé
Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells. We report from 2 clinical studies of patients with relapsed and/or refractory MM previously treated with an immunomodulatory drug and a proteasome inhibitor. Single- and multi-dosing schedules were investigated to define dose-limiting toxicities, maximum tolerated dose (MTD), recommended phase II dose, and to describe safety, efficacy, and pharmacokinetics. In the first-in-human study, indatuximab ravtansine was administered to 32 patients on day 1 of each 21-day cycle. The MTD was 160 mg/m Our data support further investigation of indatuximab ravtansine as part of a combination regimen for relapsed and/or refractory MM.
Sections du résumé
BACKGROUND
Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells.
PATIENTS AND METHODS
We report from 2 clinical studies of patients with relapsed and/or refractory MM previously treated with an immunomodulatory drug and a proteasome inhibitor. Single- and multi-dosing schedules were investigated to define dose-limiting toxicities, maximum tolerated dose (MTD), recommended phase II dose, and to describe safety, efficacy, and pharmacokinetics.
RESULTS
In the first-in-human study, indatuximab ravtansine was administered to 32 patients on day 1 of each 21-day cycle. The MTD was 160 mg/m
CONCLUSION
Our data support further investigation of indatuximab ravtansine as part of a combination regimen for relapsed and/or refractory MM.
Identifiants
pubmed: 30930134
pii: S2152-2650(18)31566-0
doi: 10.1016/j.clml.2019.02.006
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Immunoconjugates
0
indatuximab ravtansine
0
Maytansine
14083FR882
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
372-380Informations de copyright
Copyright © 2019. Published by Elsevier Inc.